When High Ferritin Is a Concern and What Usually Causes It

What High Ferritin Levels Usually Mean

About 90% of high ferritin results in routine practice come from acute phase reactions and other reactive increases, and about 10% from iron overload, according to the Sandnes et al. 2021 review. According to MedlinePlus, ferritin is a protein that binds to iron and stores it inside body tissues. MedlinePlus says the test may be ordered as part of a group of iron tests. Healthcare providers may request a 12-hour fast before the blood draw. One microgram per liter equals one nanogram per milliliter. Reference intervals vary across diagnostic laboratories. Compare your result with the range printed on your own report.

Standard laboratory thresholds establish distinct reference intervals for men and women. The Cleveland Clinic cites normal reference ranges of 15 to 205 nanograms per milliliter (ng/mL) for females and 30 to 566 ng/mL for males. In a clinical review, Sandnes et al. (Journal of Clinical Medicine, 2021) note that the upper cut-off is typically set to 200 micrograms per liter (μg/L) in women and 300 μg/L in men. About 20% of Caucasian men have ferritin levels exceeding 300 μg/L at any age. Among women aged 30 to 50, approximately 3% exceed 200 μg/L. That proportion rises to up to 17% in women older than 70 years.

Ferritin rises with stored iron and also with inflammation and damaged liver cells, so the guidelines read it next to transferrin saturation before anyone orders an HFE gene test. The European Association for the Study of the Liver (EASL) guidelines note that if serum ferritin is lower than 1,000 μg/L, the risk of severe liver fibrosis is negligible.

Medical Conditions That Cause High Ferritin

High ferritin levels stem primarily from systemic inflammatory responses, metabolic liver disorders, excess alcohol consumption, and cellular necrosis. EASL describes ferritin as an acute phase reactant that is also released from necrotic or lysed cells. The AASLD practice guideline (Bacon et al., Hepatology, 2011) lists conditions that raise ferritin without genetic hemochromatosis.

The causes the sources list fall into seven groups:

• Inflammation and acute phase reactions: MedlinePlus lists inflammation from infection or surgery and autoimmune disorders, and Sandnes et al. list acute phase reactions and infection.
• Fatty liver, metabolic syndrome, and obesity: EASL says serum ferritin is often raised in conditions linked to fatty liver disease, such as excess alcohol or the metabolic syndrome. MedlinePlus lists obesity. The guides to fatty liver and insulin resistance and metabolic syndrome cover those two conditions.
• Excessive alcohol intake: Sandnes and colleagues observed that an isolated ferritin level below 1,000 μg/L is seen in up to 40% to 70% of individuals with chronic alcohol use.
• Chronic liver disease: EASL and AASLD list acute liver injury, viral hepatitis (hepatitis B and C in AASLD) and alcohol-related liver disease. Enzyme patterns in hepatic conditions are discussed in the guide to liver function test panels.
• Renal failure and endocrine disorders: Sandnes et al. list renal failure, Cleveland Clinic lists kidney disease and diabetes, and MedlinePlus lists hyperthyroidism.
• Malignancy: Sandnes et al. say hematological and various solid malignancies may also raise ferritin. AASLD lists lymphomas.
• True iron overload: Hereditary hemochromatosis is the genetic cause, and AASLD lists dysmetabolic iron overload syndrome and porphyria cutanea tarda among conditions that raise ferritin without it.

Transferrin Saturation and Genetic Hemochromatosis Testing

EASL and AASLD both use transferrin saturation alongside ferritin to decide who gets an HFE gene test. The mathematical calculation and physiological thresholds are explained in the guide on the TIBC blood test. According to EASL guidelines, a transferrin saturation above 45% in women and above 50% in men defines a high reading. Samples should be drawn in the morning. EASL notes that fasting does not improve diagnostic utility. EASL says transferrin saturation varies a lot, which limits its usefulness.

The AASLD practice guideline recommends obtaining both transferrin saturation and ferritin when evaluating potential iron overload. If transferrin saturation is 45% or higher, or if ferritin exceeds the laboratory upper limit of normal, AASLD recommends HFE gene mutation analysis. EASL guidelines recommend testing for the p.C282Y variant in the homeostatic iron regulator (HFE) gene in individuals of European origin showing biochemical signs of overload. Specifically, EASL recommends HFE testing for females with transferrin saturation above 45% and ferritin above 200 μg/L. For males, EASL recommends testing when transferrin saturation exceeds 50% and ferritin exceeds 300 μg/L. Testing is also indicated for adult first-degree relatives of individuals diagnosed with C282Y-homozygous hemochromatosis. Unexplained persistently high transferrin saturation warrants testing even without high ferritin.

Genetic presence of the mutation does not guarantee clinical disease. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) states that hemochromatosis causes extra iron to accumulate to harmful levels. Symptoms include fatigue or weakness, joint pain, erectile dysfunction, abdominal pain over the liver, and darkened skin. EASL cites a follow-up study of 203 C282Y homozygotes aged 40 to 69, tracked for a mean of 12 years. Iron-overload-related disease developed in 28% of the men and 1.2% of the women. At baseline, 81.8% of the men and 55.4% of the women had a raised ferritin. In a separate primary-care population, 84% of homozygous men and 73% of homozygous women had a raised transferrin saturation. EASL says early diagnosis and treatment by phlebotomy can prevent cirrhosis, liver cancer (hepatocellular carcinoma), diabetes and joint disease.

Clinical Findings When Ferritin Exceeds 1,000

Sandnes et al. regard a ferritin above 1,000 μg/L as a non-specific marker of pathology that needs investigating. Sandnes and colleagues observed that more than 50% of primary care patients with ferritin above 1,000 μg/L and no obvious clinical cause receive neither secondary care referrals nor further diagnostic testing.

When ferritin exceeds 1,000 μg/L or liver enzymes are increased in hemochromatosis, guidelines recommend staging liver tissue. AASLD guidelines state that liver biopsy is recommended to stage liver disease in C282Y homozygotes or compound heterozygotes if liver enzymes are high or if ferritin exceeds 1,000 μg/L. EASL notes that liver biopsy above 1,000 μg/L may be a conservative approach given the availability of non-invasive tests.

In a clinical cohort study by Fauter et al. (Journal of Clinical Medicine, 2022), researchers evaluated 495 hospitalized patients with ferritin of 5,000 μg/L or higher across three French university hospitals over two years. Among these hospitalized patients, active infections accounted for 38.4% of cases. Hemophagocytic lymphohistiocytosis (HLH) represented 18.6%, acute hepatitis caused 14.9%, iron-overload syndromes explained 13.3%, and isolated malignancy accounted for 6.4%. In that cohort, 81% of patients had multiple underlying causes. Six-month mortality reached 47% in the cohort, rising to 61% for values exceeding 25,000 μg/L.

Medical Protocols That Lower High Ferritin

Phlebotomy is the treatment for confirmed hemochromatosis. Non-overload causes require treating the underlying inflammatory or metabolic disorder directly. For individuals with diagnosed hemochromatosis, NIDDK states that drawing about a pint of blood on a regular schedule represents the most direct way to lower iron stores. EASL guidelines recommend removing 400 to 500 mL of blood weekly or every two weeks during induction. The target induction ferritin is 50 μg/L. Maintenance phlebotomy occurs every one to four months. AASLD guidelines target a ferritin of 50 to 100 μg/L.

EASL found no conclusive evidence supporting phlebotomy for metabolic syndrome or alcohol excess. In a randomized controlled trial published in Hepatology, Adams et al. (2015) evaluated 74 adults with non-alcoholic fatty liver disease (NAFLD) over six months. Phlebotomy lowered ferritin by 148 ng/mL compared to 38 ng/mL in controls. Phlebotomy did not reduce liver fat or improve insulin resistance. Liver fat reached 17.7% in the phlebotomy arm and 15.5% in controls, while alanine aminotransferase stood at 36 versus 46 IU/L. The authors concluded that lowering ferritin by phlebotomy "does not improve liver enzymes, hepatic fat, or IR in subjects with NAFLD." A trial showing clinical benefits from iron depletion in NAFLD would change this verdict.

Dietary guidance differs between professional liver organizations. EASL states dietary changes cannot replace therapeutic phlebotomy. EASL advises avoiding iron supplements, fortified foods, and supplemental vitamin C. EASL also advises limiting red meat and alcohol. Raw seafood should be avoided to prevent Vibrio vulnificus infection. AASLD states dietary iron restrictions are unnecessary. AASLD says a low-iron diet changes iron absorption by only 2 to 4 mg a day, against the 250 mg a week that phlebotomy removes. When transferrin saturation is normal, Sandnes et al. suggest a panel that includes hemoglobin, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), liver enzymes, glucose, cholesterol, triglycerides, electrolytes and creatinine.

Ferritin Evaluation in Suspected Malignancy

High ferritin occurs in malignancies as a reactive marker without serving as a tumor screening tool. EASL classifies ferritin as an acute phase reactant, tumor marker, and angiogenesis indicator. MedlinePlus lists cancer among causes of high ferritin. Cleveland Clinic notes blood and liver cancers raise ferritin. Sandnes and colleagues say solid and hematological cancers may raise ferritin. Ferritin levels above 1,000 μg/L frequently appear in metastatic disease. Sandnes et al. say no studies have shown ferritin contributing to the cause of cancer.

In 495 hospitalized patients, Fauter and colleagues found isolated malignancy in 6.4% of cases. Infections and acute hepatitis were more common. None of the sources cited here recommends ferritin to screen for or diagnose cancer. Clinicians evaluate ferritin alongside hemoglobin from a CBC blood test and broader blood test results. Ask the clinician who ordered the ferritin test for a transferrin saturation result, the first check in the Sandnes et al. workup.